NCT05225116View on ClinicalTrials.gov

Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 8, 2023

Primary Completion Date

December 5, 2025

Study Completion Date

December 5, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Sintilimab

Sintilimab will be at a dose of 200mg,Q3W

DRUG

Lenvatinib

On the first day of the trial, Lenvatinib will be taken orally once daily （8mg/day ≤ 60kg or 12mg/day ≥60kg).

RADIATION

radiotherapy

Radiotherapy will be completed within two weeks at a dose of 300cGy× 10 fraction

Trial Locations (1)

102218

RECRUITING

Beijing Tsinghua Changgung Hospital, Beijing

All Listed Sponsors
lead

Beijing Tsinghua Chang Gung Hospital

OTHER